XEIA

XEIA Venture Partners is an early-stage venture capital firm based in San Francisco that focuses on the "Human 3" thesis—the next epoch of human health, wellbeing, and performance. Founded in 2021, the firm invests at the intersection of frontier life sciences, biotechnology, deep technology, and medtech, with a particular emphasis on neuroscience and longevity. XEIA's portfolio includes companies developing transformative solutions in brain-computer interfaces, psychedelic therapeutics, and epigenetic medicine. In addition to its investment activities, the firm operates a clinical trial recruitment and engagement platform (Xeia, Pbc) designed to accelerate the development of novel therapies.